You just read:

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

News provided by

Eureka Therapeutics, Inc.

Jan 07, 2016, 08:00 ET